{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T21:50:15Z","timestamp":1784238615810,"version":"3.55.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T00:00:00Z","timestamp":1579737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T00:00:00Z","timestamp":1579737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"crossref","award":["DRF-2018-11-ST2-028"],"award-info":[{"award-number":["DRF-2018-11-ST2-028"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>The neutrophil\u2013lymphocyte ratio (NLR) is an inflammatory biomarker which is useful in cancer prognostication. We aimed to investigate the differences in baseline NLR between patients with localised and metastatic cutaneous melanoma and how this biomarker changed over\u00a0time with the recurrence of disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This multicentre cohort study describes patients treated for Stage I\u2013III cutaneous melanoma over 10\u00a0years. The baseline NLR was measured immediately prior to surgery and again at the time of discharge or disease recurrence. The odds ratios (OR) for sentinel node involvement are estimated using mixed-effects logistic regression. The risk of recurrence is estimated using multivariable Cox regression.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Overall 1489 individuals were included. The mean baseline NLR was higher in patients with palpable nodal disease compared to those with microscopic nodal or localised disease (2.8 versus 2.4 and 2.3, respectively; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). A baseline NLR\u2009\u2265\u20092.3 was associated with 30% higher odds of microscopic metastatic melanoma in the sentinel lymph node [adjusted OR 1.3 (95% CI 1.3, 1.3)]. Following surgery, 253 patients (18.7%) developed recurrent melanoma during surveillance although there was no statistically significant association between the baseline NLR and the risk of recurrence [adjusted HR 0.9 (0.7, 1.1)].<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The NLR is associated with the volume of melanoma at presentation and may predict occult sentinel lymph metastases. Further prospective work is required to investigate how NLR may be modelled against other clinicopathological variables to predict outcomes and to understand the temporal changes in NLR following surgery for melanoma.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00262-019-02478-7","type":"journal-article","created":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T17:04:16Z","timestamp":1579799056000},"page":"559-568","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["The neutrophil\u2013lymphocyte ratio and locoregional melanoma: a multicentre cohort study"],"prefix":"10.1007","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3187-0730","authenticated-orcid":false,"given":"Alyss V.","family":"Robinson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1633-8842","authenticated-orcid":false,"given":"Claire","family":"Keeble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5937-9401","authenticated-orcid":false,"given":"Michelle C. I.","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen","family":"Thornton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7520-0344","authenticated-orcid":false,"given":"Howard","family":"Peach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4492-235X","authenticated-orcid":false,"given":"Marc D. S.","family":"Moncrieff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald J.","family":"Dewar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8365-6547","authenticated-orcid":false,"given":"Ryckie G.","family":"Wade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,23]]},"reference":[{"key":"2478_CR1","doi-asserted-by":"publisher","DOI":"10.1111\/eva.12523","author":"W You","year":"2018","unstructured":"You W, Henneberg M (2018) Cancer incidence increasing globally: the role of relaxed natural selection. Evol Appl. https:\/\/doi.org\/10.1111\/eva.12523","journal-title":"Evol Appl"},{"key":"2478_CR2","unstructured":"Stewart B, Wild (2014) International Agency for Research on Cancer. World Cancer Report 2014. World Health Organisation. https:\/\/publications.iarc.fr\/Non-Series-Publications\/World-Cancer-Reports\/World-Cancer-Report-2014"},{"key":"2478_CR3","doi-asserted-by":"publisher","first-page":"3622","DOI":"10.1200\/JCO.2001.19.16.3622","volume":"19","author":"CM Balch","year":"2001","unstructured":"Balch CM, Soong S-J, Gershenwald JE et al (2001) Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer Melanoma Staging System. J Clin Oncol 19:3622\u20133634. https:\/\/doi.org\/10.1200\/JCO.2001.19.16.3622","journal-title":"J Clin Oncol"},{"key":"2478_CR4","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1245\/ASO.2005.05.016","volume":"12","author":"SL Wong","year":"2005","unstructured":"Wong SL, Kattan MW, McMasters KM, Coit DG (2005) A nomogram that predicts the presence of sentinel node metastasis in melanoma with better discrimination than the American Joint Committee on CancerStaging System. Ann Surg Oncol 12:282\u2013288. https:\/\/doi.org\/10.1245\/ASO.2005.05.016","journal-title":"Ann Surg Oncol"},{"key":"2478_CR5","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1097\/SLA.0b013e3181b07ffd","volume":"250","author":"S Mocellin","year":"2009","unstructured":"Mocellin S, Thompson JF, Pasquali S et al (2009) Sentinel node status prediction by four statistical models: results from a large bi-institutional series (n = 1132). Ann Surg 250:964\u2013969","journal-title":"Ann Surg"},{"key":"2478_CR6","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1038\/sj.bjc.6605849","volume":"103","author":"A Mitra","year":"2010","unstructured":"Mitra A, Conway C, Walker C et al (2010) Melanoma sentinel node biopsy and prediction models for relapse and overall survival. Br J Cancer 103:1229\u20131236. https:\/\/doi.org\/10.1038\/sj.bjc.6605849","journal-title":"Br J Cancer"},{"key":"2478_CR7","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1002\/cncr.22295","volume":"107","author":"LL Kruper","year":"2006","unstructured":"Kruper LL, Spitz FR, Czerniecki BJ et al (2006) Predicting sentinel node status in AJCC stage I\/II primary cutaneous melanoma. Cancer 107:2436\u20132445. https:\/\/doi.org\/10.1002\/cncr.22295","journal-title":"Cancer"},{"key":"2478_CR8","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1245\/ASO.2006.05.011","volume":"13","author":"GC Karakousis","year":"2006","unstructured":"Karakousis GC, Gimotty PA, Botbyl JD et al (2006) Predictors of regional nodal disease in patients with thin melanomas. Ann Surg Oncol 13:533\u2013541. https:\/\/doi.org\/10.1245\/ASO.2006.05.011","journal-title":"Ann Surg Oncol"},{"key":"2478_CR9","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1245\/ASO.2004.03.044","volume":"11","author":"VK Sondak","year":"2004","unstructured":"Sondak VK, Taylor JMG, Sabel MS et al (2004) Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol 11:247\u2013258. https:\/\/doi.org\/10.1245\/ASO.2004.03.044","journal-title":"Ann Surg Oncol"},{"key":"2478_CR10","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/cncr.22382","volume":"109","author":"SC Paek","year":"2007","unstructured":"Paek SC, Griffith KA, Johnson TM et al (2007) The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. Cancer 109:100\u2013108. https:\/\/doi.org\/10.1002\/cncr.22382","journal-title":"Cancer"},{"key":"2478_CR11","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.ejso.2011.05.007","volume":"37","author":"S Pasquali","year":"2011","unstructured":"Pasquali S, Mocellin S, Campana LG et al (2011) Maximizing the clinical usefulness of a nomogram to select patients candidate to sentinel node biopsy for cutaneous melanoma. Eur J Surg Oncol 37:675\u2013680. https:\/\/doi.org\/10.1016\/j.ejso.2011.05.007","journal-title":"Eur J Surg Oncol"},{"key":"2478_CR12","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1245\/s10434-008-0077-x","volume":"15","author":"A Pi\u00f1ero","year":"2008","unstructured":"Pi\u00f1ero A, Canteras M, Ortiz E et al (2008) Validation of a nomogram to predict the presence of sentinel lymph node metastases in melanoma. Ann Surg Oncol 15:2874\u20132877. https:\/\/doi.org\/10.1245\/s10434-008-0077-x","journal-title":"Ann Surg Oncol"},{"key":"2478_CR13","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s11845-014-1166-4","volume":"184","author":"JFC Woods","year":"2015","unstructured":"Woods JFC, De Marchi JA, Lowery AJ, Hill ADK (2015) Validation of a nomogram predicting sentinel lymph node status in melanoma in an Irish population. Ir J Med Sci (1971-) 184:769\u2013773. https:\/\/doi.org\/10.1007\/s11845-014-1166-4","journal-title":"Ir J Med Sci (1971-)"},{"key":"2478_CR14","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1245\/s10434-011-1979-6","volume":"19","author":"MS Sabel","year":"2012","unstructured":"Sabel MS, Rice JD, Griffith KA et al (2012) Validation of statistical predictive models meant to select melanoma patients for sentinel lymph node biopsy. Ann Surg Oncol 19:287\u2013293. https:\/\/doi.org\/10.1245\/s10434-011-1979-6","journal-title":"Ann Surg Oncol"},{"key":"2478_CR15","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa1310460","volume":"370","author":"DL Morton","year":"2014","unstructured":"Morton DL, Thompson JF, Cochran AJ et al (2014) Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med 370:599\u2013609. https:\/\/doi.org\/10.1056\/NEJMoa1310460","journal-title":"N Engl J Med"},{"key":"2478_CR16","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.ejso.2016.06.407","volume":"43","author":"JA Moody","year":"2017","unstructured":"Moody JA, Ali RF, Carbone AC et al (2017) Complications of sentinel lymph node biopsy for melanoma\u2014a systematic review of the literature. Eur J Surg Oncol 43:270\u2013277. https:\/\/doi.org\/10.1016\/j.ejso.2016.06.407","journal-title":"Eur J Surg Oncol"},{"key":"2478_CR17","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S1470-2045(16)00141-8","volume":"17","author":"U Leiter","year":"2016","unstructured":"Leiter U, Stadler R, Mauch C et al (2016) Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol 17:757\u2013767. https:\/\/doi.org\/10.1016\/S1470-2045(16)00141-8","journal-title":"Lancet Oncol"},{"key":"2478_CR18","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/bjd.13676","volume":"172","author":"MB Faries","year":"2015","unstructured":"Faries MB, Cochran AJ, Elashoff RM, Thompson JF (2015) Multicenter selective lymphadenectomy trial-I confirms the central role of sentinel node biopsy in contemporary melanoma management. Br J Dermatol 172:571\u2013573. https:\/\/doi.org\/10.1111\/bjd.13676","journal-title":"Br J Dermatol"},{"key":"2478_CR19","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-017-6330-4","author":"MB Faries","year":"2018","unstructured":"Faries MB (2018) Completing the dissection in melanoma: increasing decision precision. Ann Surg Oncol. https:\/\/doi.org\/10.1245\/s10434-017-6330-4","journal-title":"Ann Surg Oncol"},{"key":"2478_CR20","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","volume":"377","author":"GV Long","year":"2017","unstructured":"Long GV, Hauschild A, Santinami M et al (2017) Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med 377:1813\u20131823. https:\/\/doi.org\/10.1056\/NEJMoa1708539","journal-title":"N Engl J Med"},{"key":"2478_CR21","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont AMM, Blank CU, Mandala M et al (2018) Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med 378:1789\u20131801. https:\/\/doi.org\/10.1056\/NEJMoa1802357","journal-title":"N Engl J Med"},{"key":"2478_CR22","unstructured":"National Institute for Health and Care Excellence (2018) Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma"},{"key":"2478_CR23","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1016\/S1470-2045(16)30578-2","volume":"17","author":"GV Long","year":"2016","unstructured":"Long GV, Grob JJ, Nathan P et al (2016) Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Lancet Oncol 17:1743\u20131754. https:\/\/doi.org\/10.1016\/S1470-2045(16)30578-2","journal-title":"Lancet Oncol"},{"key":"2478_CR24","doi-asserted-by":"publisher","first-page":"927","DOI":"10.3390\/cancers3010927","volume":"3","author":"X Wu","year":"2011","unstructured":"Wu X, Tomonori T, Sullivan A, Hwang ST (2011) Inflammation and tumour microenvironment in lymph node metastasis. Cancers (Basel) 3:927\u2013944. https:\/\/doi.org\/10.3390\/cancers3010927","journal-title":"Cancers (Basel)"},{"key":"2478_CR25","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/cncr.11464","volume":"98","author":"SD Nathanson","year":"2003","unstructured":"Nathanson SD (2003) Insights into the mechanisms of lymph node metastasis. Cancer 98:413\u2013423. https:\/\/doi.org\/10.1002\/cncr.11464","journal-title":"Cancer"},{"key":"2478_CR26","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nrc.2016.52","volume":"16","author":"SB Coffelt","year":"2016","unstructured":"Coffelt SB, Wellenstein MD, de Visser KE (2016) Neutrophils in cancer: neutral no more. Nat Rev Cancer 16:431\u2013446. https:\/\/doi.org\/10.1038\/nrc.2016.52","journal-title":"Nat Rev Cancer"},{"key":"2478_CR27","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s12307-012-0123-x","volume":"6","author":"DM Richards","year":"2013","unstructured":"Richards DM, Hettinger J, Feuerer M (2013) Monocytes and macrophages in cancer: development and functions. Cancer Microenviron 6:179\u2013191. https:\/\/doi.org\/10.1007\/s12307-012-0123-x","journal-title":"Cancer Microenviron"},{"key":"2478_CR28","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nrc3004","volume":"11","author":"LJ Gay","year":"2011","unstructured":"Gay LJ, Felding-Habermann B (2011) Contribution of platelets to tumour metastasis. Nat Rev Cancer 11:123\u2013134. https:\/\/doi.org\/10.1038\/nrc3004","journal-title":"Nat Rev Cancer"},{"key":"2478_CR29","doi-asserted-by":"publisher","first-page":"5383","DOI":"10.1158\/0008-5472.CAN-08-3845","volume":"69","author":"I Ray-Coquard","year":"2009","unstructured":"Ray-Coquard I, Cropet C, Van Glabbeke M et al (2009) Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res 69:5383\u20135391. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-3845","journal-title":"Cancer Res"},{"key":"2478_CR30","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/jnci\/dju124","volume":"106","author":"AJ Templeton","year":"2014","unstructured":"Templeton AJ, McNamara MG, Eruga B et al (2014) Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. JNCI J Natl Cancer Inst 106:124. https:\/\/doi.org\/10.1093\/jnci\/dju124","journal-title":"JNCI J Natl Cancer Inst"},{"key":"2478_CR31","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1158\/1055-9965.EPI-14-0146","volume":"23","author":"AJ Templeton","year":"2014","unstructured":"Templeton AJ, Ace O, McNamara MG et al (2014) Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomark Prev 23:1204\u20131212. https:\/\/doi.org\/10.1158\/1055-9965.EPI-14-0146","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"2478_CR32","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.ctrv.2015.10.003","volume":"41","author":"TF Nishijima","year":"2015","unstructured":"Nishijima TF, Muss HB, Shachar SS et al (2015) Prognostic value of lymphocyte-to-monocyte ratio in patients with solid tumors: a systematic review and meta-analysis. Cancer Treat Rev 41:971\u2013978. https:\/\/doi.org\/10.1016\/j.ctrv.2015.10.003","journal-title":"Cancer Treat Rev"},{"key":"2478_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-22425-3","author":"J Ma","year":"2018","unstructured":"Ma J, Kuzman J, Ray A et al (2018) Neutrophil-to-lymphocyte ratio (NLR) as a predictor for recurrence in patients with stage III melanoma. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-018-22425-3","journal-title":"Sci Rep"},{"key":"2478_CR34","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1002\/ijc.30215","volume":"139","author":"S Gandini","year":"2016","unstructured":"Gandini S, Ferrucci PF, Botteri E et al (2016) Prognostic significance of hematological profiles in melanoma patients. Int J Cancer 139:1618\u20131625. https:\/\/doi.org\/10.1002\/ijc.30215","journal-title":"Int J Cancer"},{"key":"2478_CR35","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1093\/annonc\/mdw016","volume":"27","author":"PF Ferrucci","year":"2016","unstructured":"Ferrucci PF, Ascierto PA, Pigozzo J et al (2016) Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. Ann Oncol 27:732\u2013738. https:\/\/doi.org\/10.1093\/annonc\/mdw016","journal-title":"Ann Oncol"},{"key":"2478_CR36","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1038\/bjc.2015.180","volume":"112","author":"PF Ferrucci","year":"2015","unstructured":"Ferrucci PF, Gandini S, Battaglia A et al (2015) Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients. Br J Cancer 112:1904\u20131910. https:\/\/doi.org\/10.1038\/bjc.2015.180","journal-title":"Br J Cancer"},{"key":"2478_CR37","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1245\/s10434-017-5836-0","volume":"24","author":"JL Davis","year":"2017","unstructured":"Davis JL, Langan RC, Panageas KS et al (2017) Elevated blood neutrophil-to-lymphocyte ratio: a readily available biomarker associated with death due to disease in high risk nonmetastatic melanoma. Ann Surg Oncol 24:1989\u20131996. https:\/\/doi.org\/10.1245\/s10434-017-5836-0","journal-title":"Ann Surg Oncol"},{"key":"2478_CR38","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/CMR.0000000000000333","volume":"27","author":"LS Lino-Silva","year":"2017","unstructured":"Lino-Silva LS, Salcedo-Hern\u00e1ndez RA, Garc\u00eda-P\u00e9rez L et al (2017) Basal neutrophil-to-lymphocyte ratio is associated with overall survival in melanoma. Melanoma Res 27:140\u2013144. https:\/\/doi.org\/10.1097\/CMR.0000000000000333","journal-title":"Melanoma Res"},{"key":"2478_CR39","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.1245\/s10434-018-6660-x","volume":"25","author":"RG Wade","year":"2018","unstructured":"Wade RG, Robinson AV, Lo MCI et al (2018) Baseline neutrophil-lymphocyte and platelet-lymphocyte ratios as biomarkers of survival in cutaneous melanoma: a multicenter cohort study. Ann Surg Oncol 25:3341\u20133349. https:\/\/doi.org\/10.1245\/s10434-018-6660-x","journal-title":"Ann Surg Oncol"},{"key":"2478_CR40","doi-asserted-by":"publisher","first-page":"i969","DOI":"10.1136\/bmj.i969","volume":"148","author":"N Pearce","year":"2016","unstructured":"Pearce N (2016) Analysis of matched case\u2013control studies. BMJ 148:i969. https:\/\/doi.org\/10.1136\/bmj.i969","journal-title":"BMJ"},{"key":"2478_CR41","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1111\/jdv.14280","volume":"31","author":"J Lyth","year":"2017","unstructured":"Lyth J, Falk M, Maroti M et al (2017) Prognostic risk factors of first recurrence in patients with primary stages I\u2013II cutaneous malignant melanoma\u2014from the population-based Swedish melanoma register. J Eur Acad Dermatol Venereol 31:1468\u20131474. https:\/\/doi.org\/10.1111\/jdv.14280","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2478_CR42","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1002\/1097-0142(20010615)91:12<2401::AID-CNCR1274>3.0.CO;2-I","volume":"91","author":"MG Statius Muller","year":"2001","unstructured":"Statius Muller MG, van Leeuwen PAM, de Lange-de Klerk ESM et al (2001) The sentinel lymph node status is an important factor for predicting clinical outcome in patients with stage I or II cutaneous melanoma. Cancer 91:2401\u20132408","journal-title":"Cancer"},{"key":"2478_CR43","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1097\/PAS.0b013e3181753a8e","volume":"32","author":"SL Van Es","year":"2008","unstructured":"Van Es SL, Colman M, Thompson JF et al (2008) Angiotropism is an independent predictor of local recurrence and in-transit metastasis in primary cutaneous melanoma. Am J Surg Pathol 32:1396\u20131403. https:\/\/doi.org\/10.1097\/PAS.0b013e3181753a8e","journal-title":"Am J Surg Pathol"},{"key":"2478_CR44","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1245\/ASO.2005.05.025","volume":"12","author":"TM Pawlik","year":"2005","unstructured":"Pawlik TM, Ross MI, Johnson MM et al (2005) Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann Surg Oncol 12:587\u2013596. https:\/\/doi.org\/10.1245\/ASO.2005.05.025","journal-title":"Ann Surg Oncol"},{"key":"2478_CR45","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1245\/s10434-016-5566-8","volume":"24","author":"M Faut","year":"2017","unstructured":"Faut M, Wevers KP, van Ginkel RJ et al (2017) Nodular histologic subtype and ulceration are tumor factors associated with high risk of recurrence in sentinel node-negative melanoma patients. Ann Surg Oncol 24:142\u2013149. https:\/\/doi.org\/10.1245\/s10434-016-5566-8","journal-title":"Ann Surg Oncol"},{"key":"2478_CR46","doi-asserted-by":"publisher","first-page":"AB10","DOI":"10.1016\/J.JAAD.2010.09.063","volume":"64","author":"F Messeguer","year":"2011","unstructured":"Messeguer F, Agusti A, Guillen C et al (2011) Prognosis and risk factors of local recurrence in cutaneous melanoma. J Am Acad Dermatol 64:AB10. https:\/\/doi.org\/10.1016\/J.JAAD.2010.09.063","journal-title":"J Am Acad Dermatol"},{"key":"2478_CR47","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/J.AMJSURG.2010.07.025","volume":"200","author":"C-CH Stucky","year":"2010","unstructured":"Stucky C-CH, Gray RJ, Dueck AC et al (2010) Risk factors associated with local and in-transit recurrence of cutaneous melanoma. Am J Surg 200:770\u2013775. https:\/\/doi.org\/10.1016\/J.AMJSURG.2010.07.025","journal-title":"Am J Surg"},{"key":"2478_CR48","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1097\/SLA.0b013e3181855718","volume":"248","author":"GW Carlson","year":"2008","unstructured":"Carlson GW, Page AJ, Cohen C et al (2008) Regional recurrence after negative sentinel lymph node biopsy for melanoma. Ann Surg 248:378\u2013386. https:\/\/doi.org\/10.1097\/SLA.0b013e3181855718","journal-title":"Ann Surg"},{"key":"2478_CR49","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1245\/s10434-016-5723-0","volume":"24","author":"TR Crookes","year":"2017","unstructured":"Crookes TR, Scolyer RA, Lo S et al (2017) Extranodal spread is associated with recurrence and poor survival in stage III cutaneous melanoma patients. Ann Surg Oncol 24:1378\u20131385. https:\/\/doi.org\/10.1245\/s10434-016-5723-0","journal-title":"Ann Surg Oncol"},{"key":"2478_CR50","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.eururo.2014.11.025","volume":"67","author":"GS Collins","year":"2015","unstructured":"Collins GS, Reitsma JB, Altman DG, Moons KGM (2015) Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. Eur Urol 67:1142\u20131151. https:\/\/doi.org\/10.1016\/j.eururo.2014.11.025","journal-title":"Eur Urol"},{"key":"2478_CR51","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(18)31559-9","volume":"392","author":"D Schadendorf","year":"2018","unstructured":"Schadendorf D, van Akkooi ACJ, Berking C et al (2018) Melanoma. Lancet 392:971\u2013984. https:\/\/doi.org\/10.1016\/S0140-6736(18)31559-9","journal-title":"Lancet"},{"key":"2478_CR52","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.cca.2018.05.055","volume":"484","author":"H Zhan","year":"2018","unstructured":"Zhan H, Ma J-Y, Jian Q-C (2018) Prognostic significance of pretreatment neutrophil-to-lymphocyte ratio in melanoma patients: a meta-analysis. Clin Chim Acta 484:136\u2013140","journal-title":"Clin Chim Acta"},{"key":"2478_CR53","doi-asserted-by":"publisher","first-page":"e11446","DOI":"10.1097\/MD.0000000000011446","volume":"97","author":"Y Ding","year":"2018","unstructured":"Ding Y, Zhang S, Qiao J (2018) Prognostic value of neutrophil-to-lymphocyte ratio in melanoma. Medicine (Baltimore) 97:e11446. https:\/\/doi.org\/10.1097\/MD.0000000000011446","journal-title":"Medicine (Baltimore)"},{"key":"2478_CR54","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1097\/00006534-199301000-00014","volume":"91","author":"S Fusi","year":"1993","unstructured":"Fusi S, Ariyan S, Sternlicht A (1993) Data on first recurrence after treatment for malignant melanoma in a large patient population. Plast Reconstr Surg 91:94\u201398","journal-title":"Plast Reconstr Surg"},{"key":"2478_CR55","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jamcollsurg.2013.03.007","volume":"217","author":"MB Faries","year":"2013","unstructured":"Faries MB, Steen S, Ye X et al (2013) Late recurrence in melanoma: clinical implications of lost dormancy. J Am Coll Surg 217:27\u201334. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2013.03.007","journal-title":"J Am Coll Surg"},{"key":"2478_CR56","doi-asserted-by":"publisher","first-page":"S109","DOI":"10.1503\/cjs.010417","volume":"60","author":"R Wade","year":"2017","unstructured":"Wade R, Robinson A, Keeble C et al (2017) Baseline neutrophil\u2013lymphocyte and platelet\u2013lymphocyte ratios are associated with survival in cutaneous malignant melanoma; abstract no 10 in the 2017 Canadian Surgery Forum Abstracts. Can J Surg 60:S109\u2013S181. https:\/\/doi.org\/10.1503\/cjs.010417","journal-title":"Can J Surg"},{"key":"2478_CR57","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/jdv.05_14275","volume":"31","author":"A Robinson","year":"2017","unstructured":"Robinson A, Keeble C, Marples M et al (2017) Baseline neutrophil\u2013lymphocyte, platelet-lymphocyte and lymphocyte\u2013monocyte ratios do not predict survival in cutaneous malignant melanoma; abstract no. FC4.4. J Eur Acad Dermatol Venereol 31:3\u2013100. https:\/\/doi.org\/10.1111\/jdv.05_14275","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-019-02478-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-019-02478-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-019-02478-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T00:39:30Z","timestamp":1611275970000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-019-02478-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,23]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["2478"],"URL":"https:\/\/doi.org\/10.1007\/s00262-019-02478-7","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,23]]},"assertion":[{"value":"25 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Approval was gained from the Research and Ethical Committees of Leeds Teaching Hospitals (reference PL15\/368) and the National Health Research Authority for Norwich (IRAS project ID: 234565). This study was conducted in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"We did not seek consent from patients to use their data in this study because this was not necessary as this was not defined as research and no new data were gathered, as determined by local ethical committee and institutional research department reviews.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}